인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 한국약제학회 Journal of Pharmaceutical Investigation Journal of Pharmaceutical Investigation 제51권 제4호
- 발행연도
- 2021.1
- 수록면
- 483 - 502 (20page)
이용수
초록· 키워드
Background Proteasome inhibitor drugs have provided a major breakthrough in the treatment of multiple myeloma and other hematological malignancies. Currently, there are three clinically used proteasome inhibitor drugs, namely bortezomib, carfilzomib, and ixazomib. Fueled by the remarkable successes of these drugs, additional drug candidates are actively pursued by targeting the proteasome and other components in the ubiquitin?proteasome pathways. Efforts are ongoing to overcome the drawbacks of the existing proteasome inhibitor drugs, optimize their pharmacokinetic aspects, and expand their clinical utility beyond the current indications, in particular for solid cancer therapy. Over the several decades, a variety of nanoparticulate delivery systems have been designed and applied to cancer therapy with a goal of improving the efficacy and safety. Area covered This review summarizes the pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and the notable findings from the recent reports on the novel nanoparticulate delivery systems of bortezomib and carfilzomib. Expert opinion With the help of novel nanoparticulate delivery systems, the therapeutic utility of the proteasome inhibitor drugs is likely to expand to various types of cancer and other pathological conditions including neurodegenerative and inflammatory diseases.
상세정보 수정요청해당 페이지 내 제목·저자·목차·페이지정보가 잘못된 경우 알려주세요!
목차
등록된 정보가 없습니다.